Current stock page

Financial Data

RYTM Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

RYTMRhythm Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$115.02+$5.16 (+4.70%)

Latest quote

  • Momentum
    72
  • Value
    52
  • Quality
    60
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$92.13M$71.26M$60.11M$57.25M$51.3M$48.5M$32.7M$41.83M
Gross Profit$79.96M$62.32M$52.96M$52.45M$45.8M$42.96M$29.06M$38.04M
Operating Income-$39.27M-$48.55M-$52.36M-$47.06M-$52.65M-$45.3M-$47M-$41.26M
Net Income-$41.37M-$49.3M-$55.64M-$47.51M-$52.9M-$46.63M-$49.5M-$43.29M
EPS-$0.61-$0.73-$0.83-$0.73-$0.82-$0.75-$0.81-$0.72
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$3.06M-$53.34M-$44.19M-$25.39M-$26.62M-$23.31M-$40.35M-$18.85M
Capital Expenditure-$500K$0$0-$953K$0$0$0$0
Free Cash Flow-$3.56M-$53.34M-$44.19M-$26.34M-$26.62M-$23.31M-$40.35M-$18.85M
Net Cash Provided By Operating Activities-$3.06M-$53.34M-$44.19M-$25.39M-$26.62M-$23.31M-$40.35M-$18.85M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$443.13M$437.27M$442.32M$480.2M$506.87M$372.73M$386.69M$392.27M
Total Debt$3.52M$3.68M$3.84M$3.99M$4.14M$4.19M$4.06M$3.94M
Cash And Cash Equivalents$39.98M$65.61M$62.14M$54.3M$52.08M$135.59M$106.1M$89.14M
Total Liabilities$241.59M$219.97M$204.7M$210.17M$211.19M$239.15M$223.6M$227.72M
Total Stockholders Equity$201.54M$217.3M$237.62M$270.03M$295.68M$133.58M$163.09M$164.55M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio38.4733.3926.4124.2922.8542.2224.9920.55
P/S ratio28.29———————
Debt To Equity0.020.020.020.010.010.030.020.02
Free Cash Flow Yield-1.64%-2.07%-1.92%-1.78%-1.62%-1.91%-2.78%-4.55%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio38.4733.3926.4124.2922.8542.2224.9920.55
P/S ratio28.29———————
Return On Equity-96.16%-94.50%-85.30%-72.79%-65.04%-137.04%-103.44%-158.35%
Debt To Equity0.020.020.020.010.010.030.020.02

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-39.66x
Pb39.4x
Revenue Growth Yoy79.59%
EPS Growth Yoy25.61%
Gross Margin88.23%
Operating Margin-66.70%
ROE-83.68%
ROIC-63.91%
Debt To Equity0.02
FCF Yield-1.60%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$115.02
Volume1.16M
RSI (14)66.28
MACD5.37
MACD signal3.14
MACD histogram2.23
ADX (14)28.46
SMA (50)$96.88
SMA (200)$97.24
ATR (14)$5.52
Historical volatility (annualized)110.93%
Volume (20-day average)1.8M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score57/100
Beta1.24
Annual volatility54.57%
Max Drawdown-35.54%
Sharpe Ratio0.52
VaR (95%, 1-day)-5.04%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

RYTM Financial Data FAQ

What is Rhythm Pharmaceuticals, Inc.'s revenue?

Rhythm Pharmaceuticals, Inc.'s revenue is one of the core financial data points for RYTM. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Rhythm Pharmaceuticals, Inc.'s revenue growing?

Revenue growth shows whether Rhythm Pharmaceuticals, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is RYTM's EPS?

RYTM's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Rhythm Pharmaceuticals, Inc.'s net income?

Rhythm Pharmaceuticals, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Rhythm Pharmaceuticals, Inc. generate?

Free cash flow shows how much cash Rhythm Pharmaceuticals, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Rhythm Pharmaceuticals, Inc. have?

Cash and debt help frame RYTM's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.